|Day Low/High||127.81 / 129.84|
|52 Wk Low/High||67.81 / 119.90|
Lower end of revenue guidance increased for FY 2017
Cramer says Abiomed is too expensive while Harman was hurt by the strong dollar.
Johnson & Johnson was easy, Cramer says, but other stocks were more problematic.
The most recent short interest data has been released for the 06/30/2016 settlement date, which shows a 365,960 share decrease in total short interest for ABIOMED, Inc. , to 2,561,708, a decrease of 12.50% since 06/15/2016.
Trade-Ideas LLC identified Abiomed (ABMD) as a new lifetime high candidate
Levi & Korsinsky announces it has commenced an investigation of Abiomed (NASDAQ: ABMD) concerning possible breaches of fiduciary duty by the board of directors of the company.
Stocks with insider trader activity include ABMD, POWI and AOS
If you're looking for high-velocity stocks in a low-velocity broader market, consider these little-known but fast-rising health care stars.
- Total Year Revenue of $329.5 Million, Up 43% Over Prior Year
Trade-Ideas LLC identified Abiomed (ABMD) as a post-market leader candidate
Entire Family of Impella Left Side Heart Pumps FDA Approved To Enable Heart Recovery
Stocks with insider trader activity include PLUG, RP and ABMD
Trade-Ideas LLC identified Abiomed (ABMD) as a weak on high relative volume candidate
Trade-Ideas LLC identified Abiomed (ABMD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Cramer doesn't like Dunkin Brands and he's not recommending Seaspan.
Investors need to remain cautious and keep their cash on the sidelines, Cramer says.
Trade-Ideas LLC identified Abiomed (ABMD) as a strong on high relative volume candidate
U.S. Patient Utilization Grew 45%, Year Over Year